Nivolumab instills hope in a hopeless situation in advanced nonsmall cell lung cancer with poor performance status

Given the favorable toxicity profile and unique mechanism of action, it is worth exploring nivolumab in the treatment of advanced nonsmall cell lung cancer with poor PS patients, who are otherwise offered only best supportive care. [3],[4] Immunotherapy is a potential modality of anticancer therapy in lung cancer and may overcome multiple adverse prognostic factors such as poor PS, smoking history, large disease burden, lack of targetable driver mutations, and heavily pretreated disease. Overall survival and long-term safety of nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer.